Intermittent endocrine therapy for advanced prostate cancer Journal Article


Authors: Klotz, L. H.; Herr, H. W.; Morse, M. J.; Whitmore, W. F. Jr
Article Title: Intermittent endocrine therapy for advanced prostate cancer
Abstract: Twenty patients with advanced prostate cancer have been treated with an intermittent endocrine therapy schedule. Hormone therapy (diethylstilbestrol in 19 patients and flutamide in 1 patient) was administered until a clinical response was clearly demonstrated and then it was withheld until symptoms recurred. Prior to treatment 17 of 20 patients had bone pain and positive radionuclide scans, two had asymptomatic pulmonary metastases, and one had symptomatic localized disease. Duration of endocrine therapy prior to withdrawal of all treatment ranged 2 to 70 months (median, 10 months). Disease progression occurred 1 to 24 months (median, 8 months) after interruption of therapy. All patients who relapsed had a rapid clinical response following resumption of endocrine therapy. Nine of ten patients rendered impotent by endocrine therapy resumed sexual activity within 3 months of stopping treatment. This data indicates that satisfactory palliation of advanced prostatic cancer can be achieved in selected patients using intermittent endocrine therapy. Copyright © 1986 American Cancer Society
Keywords: clinical article; aged; bone neoplasms; drug efficacy; palliative care; lung neoplasms; bone pain; deep vein thrombosis; prostate cancer; prostatic neoplasms; pilot projects; bone; diethylstilbestrol; hormonal therapy; drug dose; flutamide; testosterone blood level; drug therapy; testosterone; adverse drug reaction; therapy; impotence; oral drug administration; endocrine system; middle age; drug intermittent therapy; male genital system; human; male; priority journal; peripheral vascular system
Journal Title: Cancer
Volume: 58
Issue: 11
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 1986-12-01
Start Page: 2546
End Page: 2550
Language: English
DOI: 10.1002/1097-0142(19861201)58:11<2546::Aid-cncr2820581131>3.0.Co;2-n
PUBMED: 2429759
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 18 August 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Harry W Herr
    594 Herr
  2. Willet F. Whitmore Jr
    139 Whitmore
  3. Michael J. Morse
    40 Morse